Indirect Treatment Comparison between Ribociclib Combined with Non-Steroidal Aromatase Inhibitors and Ovarian Function Suppression vs. Tamoxifen in Premenopausal Women with Early Breast Cancer

In this retrospective analysis, ribociclib + NSAI + OFS demonstrated advantages across all effectiveness endpoints, including OS, in premenopausal women with HR+, HER2- early BC, without increasing overall treatment discontinuation rates compared to tamoxifen ± OFS.

Authors

Institutions

Publication Details

Journal
Geburtshilfe und Frauenheilkunde
Published
2025-04-04
DOI
https://doi.org/10.1055/a-2561-6640
Primary Topic
Advanced Breast Cancer Therapies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Indirect Treatment Comparison between Ribociclib Combined with Non-Steroidal Aromatase Inhibitors and Ovarian Function Suppression vs. Tamoxifen in Premenopausal Women with Early Breast Cancer

Stephanie Sussmann, Michael Untch, Julia Kreuzeder, D Langanke et al.
Geburtshilfe und Frauenheilkunde
Advanced Breast Cancer Therapies
article

Indirect Treatment Comparison between Ribociclib Combined with Non-Steroidal Aromatase Inhibitors and Ovarian Function Suppression vs. Tamoxifen in Premenopausal Women with Early Breast Cancer

Stephanie Sussmann, Michael Untch, Julia Kreuzeder, D Langanke, Andreas D. Hartkopf, H. Wohlgemuth, Diana Lüftner, Almuth Marx, Marc Thill, Achim Wöckel, Marcus Schmidt, Christian Roos, Maggie Banys‐Paluchowski, Andreas Schneeweiß, Manuel Hörner, Peter A. Fasching, Volkmar Müller, Wolfgang Janni, Lukas Höllrich, Julia Meinzinger, Hanna Regus-Leidig
article en

Abstract

In this retrospective analysis, ribociclib + NSAI + OFS demonstrated advantages across all effectiveness endpoints, including OS, in premenopausal women with HR+, HER2- early BC, without increasing overall treatment discontinuation rates compared to tamoxifen ± OFS.

Geburtshilfe und FrauenheilkundeVol. 85(06)
Universität Hamburg (DE), Friedrich-Alexander-Universität Erlangen-Nürnberg (DE), Johannes Gutenberg University Mainz (DE), Heidelberg University (DE), University Hospital Heidelberg (DE), Novartis (Germany) (DE), University Medical Center of the Johannes Gutenberg University Mainz (DE), St. Elisabeth-Krankenhaus Leipzig (DE), University Medical Center Hamburg-Eppendorf (DE), National Center for Tumor Diseases (DE), University Hospital Schleswig-Holstein (DE), Universitätsklinikum Würzburg (DE), Medizinische Hochschule Brandenburg Theodor Fontane (DE), Agaplesion Markus Hospital (DE), Comprehensive Cancer Center Erlangen (DE), IGES Institut (DE), Immanuel Krankenhaus (DE), University Hospital Ulm (DE), Helios Hospital Berlin-Buch (DE), University of Tübingen (DE), University of Lübeck (DE)
Novartis Pharma
Good health and well-being
Openalex Percentile: Top 90%
Advanced Breast Cancer Therapies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.